AXGT News and Press, Axovant Gene Therapies Ltd. From 09/08/20

      -  Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30 th , 2020, with leading movement disorder specialists NEW YORK and BASEL, Switzerland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies L...

Axovant Gene Therapies (NASDAQ: AXGT ) : Q2 GAAP EPS of -$0.20 beats by $0.25 . Cash and cash equivalents of $55.5M. Press Release More news on: Axovant Gene Therapies Ltd., Earnings news and commentary, ,

Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020 Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PD Company had $55.5 million of cash and cash equivalents as of June 30, 2020 NEW YORK and BASEL, Switzerland,...

Sonnet BioTherapeutics (NASDAQ: SONN ) +118% . More news on: Sonnet BioTherapeutics Holdings, Inc., electroCore, Inc., Applied DNA Sciences, Inc., Stocks on the move, , Read more ...

NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year Clinical Supply Agreement ( ...

Completed enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020 Completed enrollment of low-dose cohort of Phase 1/2 clinical study of AXO-AAV-GM1 for GM1 gangliosidosis, with data from this coh...

-  Six-month data from low-dose cohort expected in Q4 2020 -  IND amended to include Type I (infantile onset) patients and to evaluate a higher dose -  Expect to initiate high-dose cohort in 2H 2020 NEW YORK and BASEL, Switzerland, June 08, 2020 (GLOBE NEWSWIRE) -- ...

Adolescence is like having only enough light to see the step directly in front of you .” - Sarah Addison Allen Today, we take our first in depth look at a ' Tier 4 ' biotech developmental concern from across the pond. I have received a few comments around this ' off the radar ' n...

NEW YORK and BASEL, Switzerland, May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani, Pharm.D., SVP of Commercial Strategy and Operations, wi...

NEW YORK and BASEL, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million outstanding loan from Hercules Capital, Inc....